Rapid anti-suicidal effect of intravenous ketamine in resistant schizophrenia: a case report

Authors

  • Mohammad Shamsul Ahsan Associate Professor, Department of Psychiatry, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh
  • Abul Bashar Md Siddique Consultant, Department of Anesthesia, Analgesia and Intensive Care Medicine, BSMMU, Dhaka, Bangladesh
  • Ananya Kar MD Resident of Psychiatry, BSMMU, Dhaka, Bangladesh
  • Leuza Mubassara MD Resident of Child and Adolescent Psychiatry, BSMMU, Dhaka, Bangladesh

DOI:

https://doi.org/10.3329/bjpsy.v37i2.72779

Keywords:

Ketamine, Resistant schizophrenia, Suicide

Abstract

Suicide in schizophrenia is a major risk of premature death. Ketamine has been frequently shown to have immediate antidepressant effect and has a significant role to prevent suicidal attempt and plan in unipolar and bipolar depression. Though use of ketamine in severe depression with psychosis has been proven but the use in psychotic diseases has been generally ignored due to the risk of exacerbating dissociative or psychotic symptoms. We provided a case of a 43-years-old female patient suffering from schizophrenia with significant suicidal ideation and showed that ketamine infusions intravenously at a subanesthetic dose of 0.5mg/kg with a syringe pump infusion had a strong anti-suicidal impact. Importantly, no relevant psychotic or dissociative symptoms occurred during the duration of the augmentation treatment, resulting in prolonged remission of suicidality. This intervention with ketamine was safe and showed significant alleviation of suicidality which might inspire future studies.

Bang J Psychiatry 2023;37(2): 46-48

Downloads

Download data is not yet available.
Abstract
91
PDF
80

Downloads

Published

2024-07-18

How to Cite

Ahsan, M. S. ., Siddique, A. B. M. ., Kar, A. ., & Mubassara, L. . (2024). Rapid anti-suicidal effect of intravenous ketamine in resistant schizophrenia: a case report . Bangladesh Journal of Psychiatry, 37(2), 46–48. https://doi.org/10.3329/bjpsy.v37i2.72779

Issue

Vol. 37 No. 2 (2023)

Section

Case Reports

License

Copyright (c) 2023 Bangladesh Association of Psychiatrists

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Publisher of this journal, that is Bangladesh Association of Psychiatrists (BAP), is the copyright holder. As soon as the article is published, the author is considered to have transferred his/her rights to the publisher.

Creative Commons Licence
Articles in this journal are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Users are allowed to read, download, copy and distribute without asking prior permission from the publisher or the author. Requests for reproduction rights should be sent to the publisher.